T2 heterogeneity provides a sensitive measure of early tumor response to radiotherapy
M. R. Tomaszewski, W. Dominguez Viqueira, A. Ortiz, Y. Shi, J. R. Costello, H. Enderling, S. A. Rosenberg, R. J. Gillies
This paper introduces a T2 MRI-based biomarker to assess early tumor response to radiotherapy in pancreatic cancer models, showing high sensitivity and robustness.
bioRxiv · Apr 21, 2020 · PreprintBiophysics